Humacyte Inc (HUMA) - Total Assets
Based on the latest financial reports, Humacyte Inc (HUMA) holds total assets worth $91.51 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See shareholders equity of Humacyte Inc for net asset value and shareholders' equity analysis.
Humacyte Inc - Total Assets Trend (2019–2024)
This chart illustrates how Humacyte Inc's total assets have evolved over time, based on quarterly financial data.
Humacyte Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Humacyte Inc's total assets of $91.51 Million consist of 34.7% current assets and 65.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 32.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Humacyte Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see HUMA market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Humacyte Inc's current assets represent 34.7% of total assets in 2024, a decrease from 56.3% in 2019.
- Cash Position: Cash and equivalents constituted 32.6% of total assets in 2024, down from 55.6% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Humacyte Inc Competitors by Total Assets
Key competitors of Humacyte Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Humacyte Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.62 | 1.10 | 3.69 |
| Quick Ratio | 0.90 | 1.10 | -5.33 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $15.77 Million | $2.06 Million | $30.22 Million |
Humacyte Inc - Advanced Valuation Insights
This section examines the relationship between Humacyte Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 57.77 |
| Latest Market Cap to Assets Ratio | 1.20 |
| Asset Growth Rate (YoY) | 7.5% |
| Total Assets | $137.87 Million |
| Market Capitalization | $165.01 Million USD |
Valuation Analysis
Above Book Valuation: The market values Humacyte Inc's assets above their book value (1.20x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: Humacyte Inc's assets grew by 7.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Humacyte Inc (2019–2024)
The table below shows the annual total assets of Humacyte Inc from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $137.87 Million | +7.53% |
| 2023-12-31 | $128.22 Million | -37.24% |
| 2022-12-31 | $204.30 Million | -28.70% |
| 2021-12-31 | $286.53 Million | +168.57% |
| 2020-12-31 | $106.69 Million | -36.76% |
| 2019-12-31 | $168.69 Million | -- |
About Humacyte Inc
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to b… Read more